Asher Mullard

发表

2014 FDA drug approvals

Asher Mullard, 2015, Nature Reviews Drug Discovery.

Machine learning brings cell imaging promises into focus

Asher Mullard, 2019, Nature Reviews Drug Discovery.

R&D returns continue to fall

Asher Mullard, 2016, Nature Reviews Drug Discovery.

2017 FDA drug approvals

Asher Mullard, 2018, Nature Reviews Drug Discovery.

Reliability of 'new drug target' claims called into question

Asher Mullard, Asher Mullard, 2011, Nature Reviews Drug Discovery.

BACE inhibitor bust in Alzheimer trial

Asher Mullard, 2017, Nature Reviews Drug Discovery.

Sting of Alzheimer's failures offset by upcoming prevention trials

Asher Mullard, 2012, Nature Reviews Drug Discovery.

2010 FDA drug approvals

Asher Mullard, Asher Mullard, 2011, Nature Reviews Drug Discovery.

Protein–protein interaction inhibitors get into the groove

Asher Mullard, Asher Mullard, 2012, Nature Reviews Drug Discovery.

Multicompany trials adapt to disciplines beyond cancer

Asher Mullard, Asher Mullard, 2014, Nature Medicine.

Huntingtin-Interacting Protein HIP14 Is a Palmitoyl Transferase Involved in Palmitoylation and Trafficking of Multiple Neuronal Proteins

Claire-Anne Gutekunst, Michael R. Hayden, Asher Mullard, 2004, Neuron.

2018 FDA drug approvals

Asher Mullard, 2019, Nature Reviews Drug Discovery.

From the editors

Asher Mullard, Timo Hannay, F. Pentimalli, 2007, Nature Reviews Cancer.

PCSK9 inhibitors are go

Asher Mullard, 2015, Nature Reviews Drug Discovery.

Cholesterol-lowering blockbuster candidates speed into Phase III trials

Asher Mullard, 2012, Nature Reviews Drug Discovery.

Maturing antibody–drug conjugate pipeline hits 30

Asher Mullard, 2013, Nature Reviews Drug Discovery.

FDA approves female sexual dysfunction drug

Asher Mullard, 2015, Nature Reviews Drug Discovery.

Flooded by the torrent: the COVID-19 drug pipeline

Asher Mullard, 2020, The Lancet.

Alnylam dealt blow

Asher Mullard, 2009, Nature Biotechnology.

Microbial ecology: Baby boom

Asher Mullard, 2007, Nature Reviews Microbiology.

Coordinating the COVID-19 pipeline

Asher Mullard, 2020, Nature Reviews Drug Discovery.

Should everyone have an HIV test

Asher Mullard, 2008 .

FDA approves first CAR T therapy

Asher Mullard, 2017, Nature Reviews Drug Discovery.

Experimental Ebola drugs enter the limelight

Asher Mullard, 2014, The Lancet.

Tiny springboards detect viruses in fluids

Asher Mullard, 2009 .

Mechanisms of disease: Kinases out of control — brake line cut!

Asher Mullard, 2007, Nature Reviews Molecular Cell Biology.

Learning from exceptional drug responders

Asher Mullard, 2014, Nature Reviews Drug Discovery.

Skin cancer on the rise

Asher Mullard, 2009 .

EMA opens its data vaults

Asher Mullard, 2016, Nature Reviews Drug Discovery.

Industry R&D returns slip

Asher Mullard, 2015, Nature Reviews Drug Discovery.

Access to medicines report cards

Asher Mullard, 2016, Nature Reviews Drug Discovery.

FDA approves 100th monoclonal antibody product

Asher Mullard, 2021, Nature Reviews Drug Discovery.

Nine paths to PCSK9 inhibition

Asher Mullard, 2017, Nature Reviews Drug Discovery.

2015 FDA drug approvals

Asher Mullard, 2016, Nature Reviews Drug Discovery.

Pharmaceutical market growth set to slow?

Asher Mullard, 2019, Nature Reviews Drug Discovery.

FDA plans Office of Drug Evaluation Science

Asher Mullard, 2019, Nature Reviews Drug Discovery.

Arvinas’s PROTACs pass first safety and PK analysis

Asher Mullard, 2019, Nature Reviews Drug Discovery.

Targeted protein degraders crowd into the clinic

Asher Mullard, 2021, Nature Reviews Drug Discovery.

Mediator scandal engulfs French compensation body

Asher Mullard, 2013, The Lancet.

Mechanisms of disease: Perils of ageing

Asher Mullard, 2006, Nature Reviews Molecular Cell Biology.

COVID-19 vaccine development pipeline gears up

Asher Mullard, 2020, The Lancet.

Targeted degraders clear first safety hurdles

Asher Mullard, 2020, Nature Reviews Drug Discovery.

What does AlphaFold mean for drug discovery?

Asher Mullard, 2021, Nature Reviews Drug Discovery.

FDA rejects first cognitive claim for antidepressant

Asher Mullard, 2016, Nature Reviews Drug Discovery.

Anti-ageing pipeline starts to mature

Asher Mullard, 2018, Nature Reviews Drug Discovery.

EMA recommended 35 new drugs in 2017

Asher Mullard, 2018, Nature Reviews Drug Discovery.

Mediator scandal rocks French medical community

Asher Mullard, 2011, The Lancet.

Stem cells: Stemming the tide

Asher Mullard, 2016, Nature.

EMA reconsiders 'read-through' drug against Duchenne muscular dystrophy following appeal

Asher Mullard, 2014, Nature Biotechnology.

Mechanisms of disease: A spate of RAB8

Asher Mullard, 2007, Nature Reviews Molecular Cell Biology.

Genetics of cancer relapse revealed

Asher Mullard, 2008 .

Mechanisms of disease: Getting back to β-cell basics

Asher Mullard, 2008, Nature Reviews Molecular Cell Biology.

Pfizer exits neuroscience

Asher Mullard, 2018, Nature Reviews Drug Discovery.

Deuterated drugs draw heavier backing

Asher Mullard, 2016, Nature Reviews Drug Discovery.

First targeted protein degrader hits the clinic

Asher Mullard, Asher Mullard, 2019, Nature Reviews Drug Discovery.

Prions: Prions hijack the nanotube

Asher Mullard, 2009, Nature Reviews Microbiology.

Mechanisms of disease: Prions hijack the nanotube

Asher Mullard, 2009, Nature Reviews Molecular Cell Biology.

On the origin of transformative drugs

Asher Mullard, 2018, Nature Reviews Drug Discovery.

FDA approves first-in-class SYK inhibitor

Asher Mullard, 2018, Nature Reviews Drug Discovery.

Pioneering apoptosis-targeted cancer drug poised for FDA approval

Asher Mullard, 2016, Nature Reviews Drug Discovery.

Smallest biopharma firms are pushing more of the pipeline

Asher Mullard, Asher Mullard, 2019, Nature Reviews Drug Discovery.

Alzheimer prevention failure rattles field, anew

Asher Mullard, 2019, Nature Reviews Drug Discovery.

Willing subjects live longer but blur clinical trial results

Asher Mullard, 2009, Nature Medicine.

FDA approves first BCMA-targeted CAR-T cell therapy

Asher Mullard, 2021, Nature Reviews Drug Discovery.

Next-generation proteasome blockers promise safer cancer therapy

Asher Mullard, 2012, Nature Medicine.

Stem-cell discovery platforms yield first clinical candidates

Asher Mullard, 2015, Nature Reviews Drug Discovery.

Flagella and cilia come of age: Cilia and flagella formation and function

Asher Mullard, 2010 .

Antibiotics funding splurge gets mixed reception

Asher Mullard, 2016, Nature.

FDA approves anticoagulant antidote

Asher Mullard, 2015, Nature Reviews Drug Discovery.

Regulators approve the first cancer-killing virus

Asher Mullard, 2015, Nature Reviews Drug Discovery.

Oral GLP1 analogue rounds Phase II corner

Asher Mullard, 2015, Nature Reviews Drug Discovery.

FDA approves AstraZeneca’s anifrolumab for lupus

Asher Mullard, 2021, Nature Reviews Drug Discovery.

US drug spending hits $425 billion

Asher Mullard, 2016, Nature Reviews Drug Discovery.

Long COVID’s long R&D agenda

Asher Mullard, 2021, Nature Reviews Drug Discovery.

Cracking KRAS

Asher Mullard, 2019, Nature Reviews Drug Discovery.

From the editors

Louisa Flintoft, Asher Mullard, Timo Hannay, 2007, Nature Reviews Genetics.

FDA approval for Biogen’s aducanumab sparks Alzheimer disease firestorm

Asher Mullard, 2021, Nature Reviews Drug Discovery.

RECOVERY 1 year on: a rare success in the COVID-19 clinical trial landscape

Asher Mullard, 2021, Nature Reviews Drug Discovery.

FDA approves first PSMA-targeted radiopharmaceutical

Asher Mullard, 2022, Nature Reviews Drug Discovery.

NLRP3 inhibitors stoke anti-inflammatory ambitions

Asher Mullard, Asher Mullard, 2019, Nature Reviews Drug Discovery.

Should the FDA disclose complete response letters?

Asher Mullard, 2015, Nature Reviews Drug Discovery.

IDO takes a blow

Asher Mullard, 2018, Nature Reviews Drug Discovery.

Cancer metabolism pipeline breaks new ground

Asher Mullard, 2016, Nature Reviews Drug Discovery.

Molecular imaging as a de-risking tool: coming into focus?

Asher Mullard, 2013, Nature Reviews Drug Discovery.

2011 FDA drug approvals

Asher Mullard, Asher Mullard, 2012, Nature Reviews Drug Discovery.

Gene silencing: Shhh! RNAi-dependent and -independent pathways at work

Asher Mullard, 2007, Nature Reviews Molecular Cell Biology.

FDA approves Novartis's CDK4/6 inhibitor

Asher Mullard, 2017, Nature Reviews Drug Discovery.

DNA-encoded drug libraries come of age

Asher Mullard, 2016, Nature Biotechnology.

FDA approves second GPCR-targeted antibody

Asher Mullard, 2018, Nature Reviews Drug Discovery.

FDA approves fourth CAR-T cell therapy

Asher Mullard, 2021, Nature Reviews Drug Discovery.

Painkilling anti-NGF antibodies stage phase III comeback

Asher Mullard, 2018, Nature reviews. Drug discovery.

Restoring IL-2 to its cancer immunotherapy glory

Asher Mullard, 2021, Nature Reviews Drug Discovery.

Controversial Alzheimer’s drug approval could affect other diseases

Asher Mullard, 2021, Nature.

Amylyx’s ALS therapy secures FDA approval, as regulatory flexibility trumps underwhelming data

Asher Mullard, 2022, Nature Reviews Drug Discovery.

Fragile X disappointments upset autism ambitions

Asher Mullard, 2015, Nature Reviews Drug Discovery.

2021 FDA approvals

Asher Mullard, 2022, Nature Reviews Drug Discovery.

FDA approves second BCMA-targeted CAR-T cell therapy

Asher Mullard, 2022, Nature Reviews Drug Discovery.

NCI-MATCH trial pushes cancer umbrella trial paradigm

Asher Mullard, Asher Mullard, 2015, Nature Reviews Drug Discovery.

Cancer stem cell candidate Rova-T discontinued

Asher Mullard, 2019, Nature Reviews Drug Discovery.

New vaccine coalition targets epidemics

Asher Mullard, 2016, Nature Reviews Drug Discovery.

Merck &Co. drops osteoporosis drug odanacatib

Asher Mullard, 2016, Nature Reviews Drug Discovery.

FDA rejects first-in-class osteoporosis drug

Asher Mullard, 2017, Nature reviews. Drug discovery.

FDA approves first-in-class cancer metabolism drug

Asher Mullard, 2017, Nature reviews. Drug discovery.

The Roadmap Epigenomics Project opens new drug development avenues

Asher Mullard, 2015, Nature Reviews Drug Discovery.

FDA approves first anti-ANGPTL3 antibody, for rare cardiovascular indication

Asher Mullard, 2021, Nature Reviews Drug Discovery.

How COVID vaccines are being divvied up around the world.

Asher Mullard, 2020, Nature.

FDA approves first new ALS drug in over 20 years

Asher Mullard, 2017, Nature Reviews Drug Discovery.

Fragment-based screening sees the light

Asher Mullard, 2020, Nature Reviews Drug Discovery.

2019 FDA drug approvals

Asher Mullard, Asher Mullard, 2020, Nature Reviews Drug Discovery.

2017 FDA drug approvals

Asher Mullard, Asher Mullard, 2015, Nature Reviews Drug Discovery.

AbbVie pays $21 billion for Pharmacyclics' BTK inhibitor

Asher Mullard, 2015, Nature Reviews Drug Discovery.

Palmitoylation of huntingtin by HIP14is essential for its trafficking and function

Lu Gan, Asher Mullard, Catherine M Cowan, 2006, Nature Neuroscience.

Protein evolution: Tracing the evolution of structure and function

Asher Mullard, 2007, Nature Reviews Molecular Cell Biology.

From the editors

Gemma Alderton, Asher Mullard, Francesca Cesari, 2007, Nature Reviews Molecular Cell Biology.

FDA approves dupilumab for severe eczema

Asher Mullard, 2017, Nature Reviews Drug Discovery.

Alzheimer prevention hopes continue to dim

Asher Mullard, 2020, Nature Reviews Drug Discovery.

Bacterial genetics: Resistance in 18 steps

Asher Mullard, 2007, Nature Reviews Microbiology.

Tackling antimicrobial drug resistance

Asher Mullard, 2016, Nature Reviews Drug Discovery.

FDA approves first all-oral sleeping sickness drug

Asher Mullard, 2021, Nature Reviews Drug Discovery.

The drug-maker's guide to the galaxy

Asher Mullard, Asher Mullard, 2017, Nature.

First approval of a complement C3 inhibitor opens up autoimmune and inflammatory opportunities

Asher Mullard, 2021, Nature Reviews Drug Discovery.

BACE failures lower AD expectations, again

Asher Mullard, 2018, Nature Reviews Drug Discovery.

Landmark Alzheimer’s drug approval confounds research community

Asher Mullard, 2021, Nature.

Drug repurposing programmes get lift off

Asher Mullard, Asher Mullard, 2012, Nature Reviews Drug Discovery.

2013 FDA drug approvals

Asher Mullard, Asher Mullard, 2014, Nature Reviews Drug Discovery.

Do you want chips with that?

Asher Mullard, 2015, Nature Reviews Drug Discovery.

Re-assessing the rule of 5, two decades on

Asher Mullard, 2018, Nature Reviews Drug Discovery.

Crowdfunding clinical trials

Asher Mullard, 2015, Nature Reviews Drug Discovery.

EMA approves first ever malaria vaccine

Asher Mullard, 2015, Nature Reviews Drug Discovery.

Could pharma open its drug freezers?

Asher Mullard, Asher Mullard, 2011, Nature Reviews Drug Discovery.

FDA reconsiders cardiovascular outcomes trials for diabetes drugs, 10 years on

Asher Mullard, 2018, Nature Reviews Drug Discovery.

How much do phase III trials cost?

Asher Mullard, 2018, Nature Reviews Drug Discovery.

First de novo deuterated drug poised for approval

Asher Mullard, 2022, Nature Reviews Drug Discovery.

New drugs cost US$2.6 billion to develop

Asher Mullard, 2014, Nature Reviews Drug Discovery.

The anticounterfeiter's technological tool kit

Asher Mullard, 2010, Nature Medicine.

FDA approves Eli Lilly's baricitinib

Asher Mullard, 2018, Nature Reviews Drug Discovery.

mRNA vaccines get another booster

Asher Mullard, 2018, Nature Reviews Drug Discovery.

FDA advisory committee votes for approval of first microbiome-based drug, despite data problems

Asher Mullard, 2022, Nature Reviews Drug Discovery.

A probe for every protein

Asher Mullard, Asher Mullard, 2019, Nature Reviews Drug Discovery.

Sepsis researchers set sights on immunotherapeutic strategies

Asher Mullard, 2018, Nature Reviews Drug Discovery.

Phosphatases start shedding their stigma of undruggability

Asher Mullard, Asher Mullard, 2018, Nature Reviews Drug Discovery.

Blood–brain barrier-traversing biologic secures regulatory approval, in Japan

Asher Mullard, 2021, Nature Reviews Drug Discovery.

GSK's darapladib failures dim hopes for anti-inflammatory heart drugs

Asher Mullard, 2014, Nature Reviews Drug Discovery.

Antibody–oligonucleotide conjugates enter the clinic

Asher Mullard, 2021, Nature reviews. Drug discovery.

Roche’s anti-TIGIT drug suffers a phase III cancer setback

Asher Mullard, 2022, Nature Reviews Drug Discovery.

Chinese biopharma starts feeding the global pipeline

Asher Mullard, 2017, Nature Reviews Drug Discovery.

Tatsuya Kondo

Asher Mullard, T. Kondo, 2014, Nature Reviews Drug Discovery.

Addressing cancer’s grand challenges

Asher Mullard, 2020, Nature Reviews Drug Discovery.

Second anticancer CAR T therapy receives FDA approval

Asher Mullard, Asher Mullard, 2017, Nature Reviews Drug Discovery.

BTK inhibitors get a boost

Asher Mullard, Asher Mullard, 2017, Nature Reviews Drug Discovery.

ALS antisense drug falters in phase III

Asher Mullard, 2021, Nature Reviews Drug Discovery.

Parsing clinical success rates

Asher Mullard, Asher Mullard, 2016, Nature Reviews Drug Discovery.

Drug withdrawal sends critical care specialists back to basics

Asher Mullard, 2011, The Lancet.

2016 FDA drug approvals

Asher Mullard, Asher Mullard, 2017, Nature Reviews Drug Discovery.

Trispecific antibodies take to the clinic

Asher Mullard, 2020, Nature Reviews Drug Discovery.

The phenotypic screening pendulum swings

Asher Mullard, Asher Mullard, 2015, Nature Reviews Drug Discovery.

John P. A. Ioannidis

J. Ioannidis, Asher Mullard, 2014, Nature reviews. Drug discovery.

2012 FDA drug approvals

Asher Mullard, 2013, Nature Reviews Drug Discovery.

The Nobel Prize-winning path from oxygen sensing research to new drugs.

Asher Mullard, 2021, Nature reviews. Drug discovery.

Stemming the tide of drug resistance in cancer

Asher Mullard, 2020, Nature Reviews Drug Discovery.

Novartis’s canakinumab stumbles in cancer, again

Asher Mullard, 2021, Nature Reviews Drug Discovery.

23andMe sets sights on UK/Canada, signs up Genentech

Asher Mullard, 2015, Nature Biotechnology.

FDA approves first new flu drug in 20 years

Asher Mullard, 2018, Nature Reviews Drug Discovery.

New plaque psoriasis approval carries suicide warning

Asher Mullard, 2017, Nature Reviews Drug Discovery.

Maturing antibody–drug conjugate pipeline hits 30

Asher Mullard, Asher Mullard, 2013, Nature Reviews Drug Discovery.

Anti-amyloid failures stack up as Alzheimer antibody flops

Asher Mullard, 2019, Nature Reviews Drug Discovery.

p53 programmes plough on

Asher Mullard, 2020, Nature Reviews Drug Discovery.

Small molecules against RNA targets attract big backers

Asher Mullard, 2017, Nature Reviews Drug Discovery.

First targeted protein degrader hits the clinic

Asher Mullard, 2019, Nature Reviews Drug Discovery.

2010 FDA drug approvals

Asher Mullard, 2011, Nature Reviews Drug Discovery.

DNA repair: Making the cut

Asher Mullard, 2006, Nature Reviews Molecular Cell Biology.

Presynaptic Trafficking of Synaptotagmin I Is Regulated by Protein Palmitoylation*

Asher Mullard, W. Honer, A. El-Husseini, 2004, Journal of Biological Chemistry.

The art of losing

Asher Mullard, 2015, The Lancet.

Microbiology: The inside story

Asher Mullard, 2008, Nature.

Biomolecular condensates pique drug discovery curiosity

Asher Mullard, 2019, Nature Reviews Drug Discovery.

Gene therapy community grapples with toxicity issues, as pipeline matures

Asher Mullard, 2021, Nature Reviews Drug Discovery.

DNA tags help the hunt for drugs

Asher Mullard, Asher Mullard, 2016, Nature.

FDA approval of Immunocore’s first-in-class TCR therapeutic broadens depth of the T cell engager platform

Asher Mullard, 2022, Nature Reviews Drug Discovery.

Bracing for the biosimilar wave

Asher Mullard, 2017, Nature Reviews Drug Discovery.

Can innate immune system targets turn up the heat on 'cold' tumours?

Asher Mullard, 2017, Nature Reviews Drug Discovery.

Sarepta’s DMD gene therapy falls flat

Asher Mullard, 2021, Nature reviews. Drug discovery.

Success of immunomodulators in MS shifts discovery focus to neuroprotection

Asher Mullard, 2011, Nature reviews. Drug discovery.

Remyelination researchers regroup after proof-of-concept setback in multiple sclerosis

Asher Mullard, 2016, Nature Reviews Drug Discovery.

FDA approves first anti-IL-36 receptor antibody for rare skin disease

Asher Mullard, 2022, Nature Reviews Drug Discovery.

Unleashing the Mini-Sentinel

Asher Mullard, Asher Mullard, 2012, Nature Reviews Drug Discovery.

Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating

Asher Mullard, 2020, Nature reviews. Drug discovery.

Fragile X drug development flounders

Asher Mullard, 2016, Nature reviews. Drug discovery.

Momentum builds around new antibiotic business models

Asher Mullard, 2014, Nature Reviews Drug Discovery.

Making way for maternal immunization

Asher Mullard, 2015, Nature Reviews Drug Discovery.

2015 FDA drug approvals

Asher Mullard, Asher Mullard, 2016, Nature Reviews Drug Discovery.

Can next-generation antibodies offset biosimilar competition?

Asher Mullard, Asher Mullard, 2012, Nature Reviews Drug Discovery.

FDA approves first immunotherapy combo

Asher Mullard, Asher Mullard, 2015, Nature Reviews Drug Discovery.

EMA greenlights Novartis' first-in-class IL-17 inhibitor

Asher Mullard, Asher Mullard, 2014, Nature Reviews Drug Discovery.

European regulators approve first PARP inhibitor

Asher Mullard, 2014, Nature reviews. Drug discovery.

NLRP3 inhibitors stoke anti-inflammatory ambitions

Asher Mullard, 2019, Nature reviews. Drug discovery.

Use of personalized cancer drugs runs ahead of the science

Asher Mullard, 2015, Nature.

FDA approves first peanut allergy drug

Asher Mullard, 2020, Nature Reviews Drug Discovery.

FDA approves first marijuana-derived product

Asher Mullard, 2018, Nature Reviews Drug Discovery.

A snapshot of lead-generation strategies

Asher Mullard, Asher Mullard, 2018, Nature Reviews Drug Discovery.

Microfluidics platform lowers barrier to drug combination screening

Asher Mullard, 2018, Nature Reviews Drug Discovery.

RNAi agents score an approval and drive an acquisition

Asher Mullard, 2019, Nature Reviews Drug Discovery.

The cancer vaccine resurgence

Asher Mullard, 2016, Nature Reviews Drug Discovery.

FDA approves landmark RNAi drug

Asher Mullard, 2018, Nature Reviews Drug Discovery.

BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval

Asher Mullard, 2022, Nature Reviews Drug Discovery.

The quest to prevent MS — and understand other post-viral diseases

Asher Mullard, 2022, Nature.

2022 FDA approvals

Asher Mullard, 2023, Nature Reviews Drug Discovery.

EU implicated in controversial counterfeiting bill

Asher Mullard, 2010, The Lancet.

More Alzheimer’s drugs head for FDA review: what scientists are watching

Asher Mullard, 2021, Nature.

Malaria medicine box expands

Asher Mullard, 2018, Nature reviews. Drug discovery.

Can you trust your cancer cell lines?

Asher Mullard, 2018, Nature reviews. Drug discovery.

FDA approves an inhibitor of a novel ‘epigenetic writer’

Asher Mullard, 2020, Nature reviews. Drug discovery.

Archaea: Kings of the sea floor?

Asher Mullard, 2008, Nature Reviews Microbiology.

2013 in reflection

Asher Mullard, 2013, Nature Reviews Drug Discovery.

New checkpoint inhibitors ride the immunotherapy tsunami

Asher Mullard, 2013, Nature Reviews Drug Discovery.

$1.3 billion per drug?

Asher Mullard, 2020, Nature reviews. Drug discovery.

FDA approves first EGFR exon 20 targeted kinase inhibitor

Asher Mullard, 2021, Nature Reviews Drug Discovery.

Dual fronts poised to transform melanoma therapy

Asher Mullard, 2011, Nature Reviews Drug Discovery.

Cancer reproducibility project yields first results

Asher Mullard, 2017, Nature reviews. Drug discovery.

FDA notches up third tissue-agnostic cancer approval

Asher Mullard, 2019, Nature Reviews Drug Discovery.

Gene therapy boom continues

Asher Mullard, 2019, Nature Reviews Drug Discovery.

NIH tackles clinical trial shortcomings

Asher Mullard, 2016, Nature Reviews Drug Discovery.

Anti-tau antibody failures stack up

Asher Mullard, 2021, Nature Reviews Drug Discovery.

Immunotherapy interest drives IDO deals

Asher Mullard, 2015, Nature reviews. Drug discovery.

CRISPR technologies are going to need a bigger toolbox

Asher Mullard, 2021, Nature reviews. Drug discovery.

FDA approves bispecific antibody for two eye diseases

Asher Mullard, 2022, Nature reviews. Drug discovery.

Climbing cancer’s MYC mountain

Asher Mullard, 2022, Nature Reviews Drug Discovery.

Husseini Manji

H. Manji, Asher Mullard, 2015, Nature Reviews Drug Discovery.

Alzheimer amyloid hypothesis lives on

Asher Mullard, 2016, Nature Reviews Drug Discovery.

Mechanisms of disease: Inhibiting γ-secretase activity

Asher Mullard, Asher Mullard, 2007, Nature Reviews Molecular Cell Biology.

Cardiovascular pipeline decline quantified

Asher Mullard, 2016, Nature Reviews Drug Discovery.

COVID antibody drugs have saved lives — so why aren’t they more popular?

Asher Mullard, 2022, Nature.

IRAK4 degrader to take on innate immunity

Asher Mullard, 2020, Nature Biotechnology.

FDA approves RNA-targeting small molecule

Asher Mullard, 2020, Nature Reviews Drug Discovery.

FDA approves first deuterated drug

Asher Mullard, 2017, Nature Reviews Drug Discovery.

Malaria vaccine shows phase II promise, advances into phase III

Asher Mullard, 2021, Nature Reviews Drug Discovery.

Microscopy: Eukaryotic cell, now showing in 3D

Asher Mullard, 2007, Nature reviews. Molecular cell biology.

FDA approves first bispecific

Asher Mullard, Asher Mullard, 2014, Nature Reviews Drug Discovery.

mRNA-based drug approaches Phase I milestone

Asher Mullard, 2016, Nature Reviews Drug Discovery.

LAG3 pushes immuno-oncology’s leading edge

Asher Mullard, 2022, Nature Reviews Drug Discovery.

FDA approves first haemophilia B gene therapy

Asher Mullard, 2022, Nature Reviews Drug Discovery.

Straight talk with...Phil Willis

Asher Mullard, 2011, Nature Medicine.

Synthetic lethality screens point the way to new cancer drug targets

Asher Mullard, 2017, Nature Reviews Drug Discovery.

Synthetic lethality screens point the way to new cancer drug targets

Asher Mullard, 2017, Nature Reviews Drug Discovery.

Drug developers reboot anti-NGF pain programmes

Asher Mullard, 2015, Nature Reviews Drug Discovery.

COVID-19 vaccine success enables a bolder vision for mRNA cancer vaccines, says BioNTech CEO

Asher Mullard, 2021, Nature Reviews Drug Discovery.

FDA approves decades-old maribavir for CMV infection

Asher Mullard, 2021, Nature reviews. Drug discovery.

Failure of Seres’s phase II ulcerative colitis programme renews microbiome concerns

Asher Mullard, 2021, Nature Reviews Drug Discovery.

Parkinson disease setback

Asher Mullard, 2020, Nature Reviews Drug Discovery.

Jim O'Neill

Asher Mullard, 2016, Nature Reviews Drug Discovery.

FDA approves fifth RNAi drug — Alnylam’s next-gen hATTR treatment

Asher Mullard, 2022, Nature Reviews Drug Discovery.

EMA provides first glimpse of PRIME candidates

Asher Mullard, Asher Mullard, 2016, Nature Reviews Drug Discovery.

Robust biotech sector increases R&D spend

Asher Mullard, 2015, Nature Reviews Drug Discovery.

First antibody against COVID-19 spike protein enters phase I

Asher Mullard, 2020, Nature Reviews Drug Discovery.

FDA approves antitoxin antibody

Asher Mullard, 2016, Nature Reviews Drug Discovery.

BACE race gains steam

Asher Mullard, Asher Mullard, 2016, Nature Reviews Drug Discovery.

Microbiology: Tinker, bacteria, eukaryote, spy

Asher Mullard, 2009, Nature.

Pharma pumps up anti-tau Alzheimer pipeline despite first Phase III failure

Asher Mullard, 2016, Nature Reviews Drug Discovery.

2020 FDA drug approvals

Asher Mullard, 2021, Nature Reviews Drug Discovery.

FDA rejects NASH drug

Asher Mullard, 2020, Nature Reviews Drug Discovery.

2015 FDA drug approvals

Asher Mullard, 2016, Nature Reviews Drug Discovery.

2014 FDA drug approvals

Asher Mullard, 2015, Nature Reviews Drug Discovery.

The UK Biobank at 20

Asher Mullard, 2022, Nature Reviews Drug Discovery.

Bispecific antibody pipeline moves beyond oncology

Asher Mullard, 2017, Nature Reviews Drug Discovery.

Anti-amyloid failures stack up as Alzheimer antibody flops

Asher Mullard, 2019, Nature Reviews Drug Discovery.

Microglia-targeted candidates push the Alzheimer drug envelope

Asher Mullard, 2018, Nature Reviews Drug Discovery.

PARP inhibitor pick-me-up

Asher Mullard, 2019, Nature Reviews Drug Discovery.

REVAMPing antibiotic incentives

Asher Mullard, 2018, Nature Reviews Drug Discovery.

Biotech R&D spend jumps by more than 15%

Asher Mullard, Asher Mullard, 2016, Nature Reviews Drug Discovery.

Vertex’s NaV1.8 inhibitor passes phase II pain point

Asher Mullard, 2022, Nature Reviews Drug Discovery.

European Lead Factory opens for business

Asher Mullard, Asher Mullard, 2013, Nature Reviews Drug Discovery.